Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences.
Interested parties may access live and archived webcasts of the sessions on the "Investors" section of the company website at: www.guardanthealth.com.
About Guardant Health
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNexttm, Guardant360 Responsetm, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Revealtm for early-stage cancer patients. The Guardant Health screening portfolio, including the commercially launched Shieldtm test, aims to address the needs of individuals eligible for cancer screening.
These press releases may also interest you
|